Effect of tirofiban combined with PCI on myocardial damage and platelet activation in patients with STEMI

Objective: To study the effect of tirofiban combined with PCI on myocardial damage and platelet activation in patients with STEMI. Methods: Patients with STEMI who were treated and underwent PCI in Wujiang First People’s Hospital in Suzhou between March 2015 and February 2017 were selected as the research subjects and randomly divided into two groups, intervention group received tirofiban combined with PCI therapy, control group received routine PCI therapy, and the myocardial damage indexes and platelet activation indexes of two groups of patients were detected. Results: 24 h after PCI treatment, serum S100A/B, H-FABP, GDF-15, cTnT, FKN, MDA, sFas, sTWEAK and 8-OHdG levels of intervention group were obviously lower than those of control group; before PCI treatment and 24 h after PCI treatment, peripheral blood CD62p and PAC-1 expression intensity as well as serum P-selectin, thrombospondin and CD40 ligand levels of intervention group were obviously lower than those of control group. Conclusion: Tirofiban therapy before PCI can help alleviate myocardial damage and inhibit platelet activation.